News | December 30, 2025
Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
